Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jul 2;75(1):75–83. doi: 10.1136/annrheumdis-2015-207511

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

PMC Copyright notice

(A) Clinical remission rates at weeks 24 and 52 by Simple Disease Activity Index (SDAI), Boolean and Disease Activity Score 28-joint assessment (DAS28) (erythrocyte sedimentation rate (ESR)) criteria analysed using full analysis set (FAS), last observation carried forward (LOCF) data set. Error bars indicate 95% confidence interval of each remission rate. P values are calculated by Fisher's exact test. (B-E) Time course of American College of Rheumatology (ACR) response rates of (B) ACR20, (C) ACR50, (D) ACR70 and (E) Health Assessment Questionnaire Disability Index (HAQ-DI) remission rates. *p<0.05 between the groups at each particular time point, calculated by Fisher's exact test. CZP, certolizumab pegol; MTX, methotrexate; PBO, placebo.